Al-Ani, M.; Baraka, B.; Mathiyalagan, N.; Sarwar, M.A.; Segaran, A.; Abuzahra, W.; Radford, A.; Buxton, K.; Seneviratne, L.; Sundar, S.;
et al. The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. Cancers 2025, 17, 3591.
https://doi.org/10.3390/cancers17213591
AMA Style
Al-Ani M, Baraka B, Mathiyalagan N, Sarwar MA, Segaran A, Abuzahra W, Radford A, Buxton K, Seneviratne L, Sundar S,
et al. The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. Cancers. 2025; 17(21):3591.
https://doi.org/10.3390/cancers17213591
Chicago/Turabian Style
Al-Ani, Maryam, Bahaaeldin Baraka, Navin Mathiyalagan, Muhammad Adeel Sarwar, Avinash Segaran, Wafaa Abuzahra, Alayna Radford, Kersty Buxton, Lalith Seneviratne, Santhanam Sundar,
and et al. 2025. "The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers" Cancers 17, no. 21: 3591.
https://doi.org/10.3390/cancers17213591
APA Style
Al-Ani, M., Baraka, B., Mathiyalagan, N., Sarwar, M. A., Segaran, A., Abuzahra, W., Radford, A., Buxton, K., Seneviratne, L., Sundar, S., Anand, A., Nunns, D., Williamson, K., Wormald, B., Gajjar, K., & Madhusudan, S.
(2025). The Real-World Impact of PARP Inhibitor Maintenance Therapy in High Grade Serous Tubo-Ovarian and Peritoneal Cancers. Cancers, 17(21), 3591.
https://doi.org/10.3390/cancers17213591
